Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical and functional characterisation
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Juan Manuel Lebron Ramos (Marbella, Spain), Juan Manuel Lebron Ramos, Luis Fernandez de Rota Garcia, Alicia Padilla Galo, Begoña Tortajada Goitia, Jose Joaquin Cebrian Gallardo, Francisco Rivas Ruiz. Effectiveness of inhaled colistin by iNeb® device in non-CF bronchiectasis and chronic pseudomonas infection. Eur Respir J 2015; 46: Suppl. 59, 2625

Member's Comments

No comment yet.

Related content which might interest you: Inhaled colistin in patients with non - cystic fibrosis bronchiectasis and chronic pseudomonas aeruginosa bronquial infection Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Patients with no cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa: Role of inhaled colistin Source: International Congress 2014 – Epidemiology, scores and outcomes of respiratory infections Year: 2014 Inhaled colistin in elderly patients with bronchiectasis and chronic bronchial infection with pseudomonas Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Effect of long term azithromycin on exacerbations in non CF bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Efficacy and safety of inhaled antibiotics for chronic pseudomonas infection in cystic fibrosis: Network meta-analysis Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Azithromycin therapy and pseudomonas aeruginosa isolation in a non-cystic fibrosis bronchiectasis cohort Source: International Congress 2015 – Adult bronchiectasis: risk factors and future perspectives Year: 2015 The low dose macrolides for prevention of exacerbations in non-CF bronchiectasis Source: International Congress 2015 – Management of asthma and other respiratory diseases in primary care Year: 2015 Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Role of stenotrophomonas maltophilia infection in CF pulmonary exacerbations Source: Annual Congress 2013 –Difficult and rare respiratory infections Year: 2013 Acute exacerbations of COPD due to pseudomonas aeruginosa: Impact of antimicrobial resistance Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 Inhaled antimicrobials Source: ERS webinar 2020: Inhaled antimicrobials Year: 2020 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Nicotinamide and bacterial killing in patients with non-cystic fibrosis bronchiectasis Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013 Inhaled antibiotics in chronic airway infections Source: Eur Respir Monogr 2017; 75: 57-79 Year: 2017 The clinical impact of nebulised antibiotics in adults with bronchiectasis and chronic pseudomonas aeruginosa Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020 COPD and pseudomonas aeruginosa, an association Source: International Congress 2014 – Resistance, bacteriological profile and comorbidities in respiratory infections Year: 2014